BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38580331)

  • 1. Targeting of netrin-1 by monoclonal antibody NP137 inhibits the EMT in cancer.
    Xia X; Yin K; Wang S
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580331
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological targeting of netrin-1 inhibits EMT in cancer.
    Lengrand J; Pastushenko I; Vanuytven S; Song Y; Venet D; Sarate RM; Bellina M; Moers V; Boinet A; Sifrim A; Rama N; Ducarouge B; Van Herck J; Dubois C; Scozzaro S; Lemaire S; Gieskes S; Bonni S; Collin A; Braissand N; Allard J; Zindy E; Decaestecker C; Sotiriou C; Salmon I; Mehlen P; Voet T; Bernet A; Blanpain C
    Nature; 2023 Aug; 620(7973):402-408. PubMed ID: 37532929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer.
    Cassier PA; Navaridas R; Bellina M; Rama N; Ducarouge B; Hernandez-Vargas H; Delord JP; Lengrand J; Paradisi A; Fattet L; Garin G; Gheit H; Dalban C; Pastushenko I; Neves D; Jelin R; Gadot N; Braissand N; Léon S; Degletagne C; Matias-Guiu X; Devouassoux-Shisheboran M; Mery-Lamarche E; Allard J; Zindy E; Decaestecker C; Salmon I; Perol D; Dolcet X; Ray-Coquard I; Blanpain C; Bernet A; Mehlen P
    Nature; 2023 Aug; 620(7973):409-416. PubMed ID: 37532934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors.
    Kryza D; Wischhusen J; Richaud M; Hervieu M; Sidi Boumedine J; Delcros JG; Besse S; Baudier T; Laval PA; Breusa S; Boutault E; Clermidy H; Rama N; Ducarouge B; Devouassoux-Shisheboran M; Chezal JM; Giraudet AL; Walter T; Mehlen P; Sarrut D; Gibert B
    EMBO Mol Med; 2023 Apr; 15(4):e16732. PubMed ID: 36876343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Targeting netrin-1 to inhibit epithelial-mesenchymal transition: a new insight for cancer therapy].
    Braissand N; Bernet A
    Med Sci (Paris); 2024 Feb; 40(2):124-126. PubMed ID: 38411414
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting netrin-3 in small cell lung cancer and neuroblastoma.
    Jiang S; Richaud M; Vieugué P; Rama N; Delcros JG; Siouda M; Sanada M; Redavid AR; Ducarouge B; Hervieu M; Breusa S; Manceau A; Gattolliat CH; Gadot N; Combaret V; Neves D; Ortiz-Cuaran S; Saintigny P; Meurette O; Walter T; Janoueix-Lerosey I; Hofman P; Mulligan P; Goldshneider D; Mehlen P; Gibert B
    EMBO Mol Med; 2021 Apr; 13(4):e12878. PubMed ID: 33719214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness.
    Liao TT; Yang MH
    Mol Oncol; 2017 Jul; 11(7):792-804. PubMed ID: 28649800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.
    Palena C; Hamilton DH
    Adv Cancer Res; 2015; 128():69-93. PubMed ID: 26216630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.
    Taki M; Abiko K; Ukita M; Murakami R; Yamanoi K; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M
    Clin Cancer Res; 2021 Sep; 27(17):4669-4679. PubMed ID: 33827891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
    Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Netrin-1 elicits metastatic potential of non-small cell lung carcinoma cell by enhancing cell invasion, migration and vasculogenic mimicry via EMT induction.
    Zhang X; Cui P; Ding B; Guo Y; Han K; Li J; Chen H; Zhang W
    Cancer Gene Ther; 2018 Feb; 25(1-2):18-26. PubMed ID: 29234153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Plasticity and Resistance to Immunotherapy.
    Horn LA; Fousek K; Palena C
    Trends Cancer; 2020 May; 6(5):432-441. PubMed ID: 32348738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells.
    Zhang PF; Huang Y; Liang X; Li D; Jiang L; Yang X; Zhu M; Gou HF; Gong YL; Wei YQ; Li Q; Wang W
    FASEB J; 2020 Aug; 34(8):11185-11199. PubMed ID: 32645243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Netrin-1 induces epithelial-mesenchymal transition and promotes hepatocellular carcinoma invasiveness.
    Yan W; Han P; Zhou Z; Tu W; Liao J; Li P; Liu M; Tian D; Fu Y
    Dig Dis Sci; 2014 Jun; 59(6):1213-21. PubMed ID: 24442237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.
    Cui B; Zhang S; Chen L; Yu J; Widhopf GF; Fecteau JF; Rassenti LZ; Kipps TJ
    Cancer Res; 2013 Jun; 73(12):3649-60. PubMed ID: 23771907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
    Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
    IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay of Immunometabolism and Epithelial-Mesenchymal Transition in the Tumor Microenvironment.
    Chou MY; Yang MH
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Netrin-1 expression and targeting in multiple myeloma.
    Fahed D; Chettab A; Mathe D; Denis M; Traverse-Glehen A; Karlin L; Perrial E; Dumontet C
    Leuk Lymphoma; 2022 Feb; 63(2):395-403. PubMed ID: 34585999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the epithelial-to-mesenchymal transition clinically relevant for the cancer patient?
    Krasnapolski MA; Todaro LB; de Kier Joffé EB
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1891-9. PubMed ID: 21470129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.